000132679 001__ 132679
000132679 005__ 20240229105026.0
000132679 0247_ $$2doi$$a10.1007/s10549-017-4608-7
000132679 0247_ $$2pmid$$apmid:29235043
000132679 0247_ $$2ISSN$$a0167-6806
000132679 0247_ $$2ISSN$$a1573-7217
000132679 0247_ $$2altmetric$$aaltmetric:30445114
000132679 037__ $$aDKFZ-2018-00339
000132679 041__ $$aeng
000132679 082__ $$a610
000132679 1001_ $$avan Vulpen, Jonna K$$b0
000132679 245__ $$aEffects of physical exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy.
000132679 260__ $$aDordrecht [u.a.]$$bSpringer Science + Business Media B.V.$$c2018
000132679 3367_ $$2DRIVER$$aarticle
000132679 3367_ $$2DataCite$$aOutput Types/Journal article
000132679 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525334286_2482
000132679 3367_ $$2BibTeX$$aARTICLE
000132679 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000132679 3367_ $$00$$2EndNote$$aJournal Article
000132679 500__ $$avan Vulpen JK*, Schmidt ME* (First Authors) * shared positionsMay AM*, Steindorf K*  (Last Authors) * shared positionsshared positions
000132679 520__ $$aExercise has been shown to reduce fatigue during cancer treatment. Hypothesized mechanisms include inflammatory pathways. Therefore, we investigated effects of exercise on markers of inflammation in breast cancer patients during adjuvant chemotherapy.We pooled data from two randomized controlled exercise intervention trials with breast cancer patients during adjuvant chemotherapy (n = 130), which had previously shown beneficial effects of exercise on fatigue. Exercise comprised a 12-week resistance training (BEATE study) or an 18-week combined resistance and aerobic training (PACT study). Serum IL-6, IL-1ra, and the IL-6/IL-1ra ratio were quantified at baseline, mid-intervention, post-intervention, and 6-9 months post-baseline.Mixed effect models showed significant increases in IL-6 and IL-6/IL-1ra ratio during chemotherapy and decreases afterwards. Differences between exercise and control group were not significant at any time point. Changes in total cancer-related fatigue were significantly correlated with changes in IL-6/IL-1ra ratio (partial correlation r = 0.23) and IL-6 (r = 0.21), and changes in physical cancer-related fatigue with changes in IL-6/IL-1ra ratio (r = 0.21).Changes in fatigue were slightly correlated with changes in inflammatory markers, and there was a strong inflammatory response to adjuvant chemotherapy. The supervised exercise training did not counteract this increase in inflammation, suggesting that beneficial effects of exercise on fatigue during adjuvant chemotherapy for breast cancer are not essentially mediated by IL-6, IL-1ra, or the IL-6/IL-1ra ratio.
000132679 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000132679 588__ $$aDataset connected to CrossRef, PubMed,
000132679 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b1$$eFirst author$$udkfz
000132679 7001_ $$aVelthuis, Miranda J$$b2
000132679 7001_ $$aWiskemann, Joachim$$b3
000132679 7001_ $$aSchneeweiss, Andreas$$b4
000132679 7001_ $$aVermeulen, Roel C H$$b5
000132679 7001_ $$aHabermann, Nina$$b6
000132679 7001_ $$aUlrich, Cornelia M$$b7
000132679 7001_ $$aPeeters, Petra H M$$b8
000132679 7001_ $$avan der Wall, Elsken$$b9
000132679 7001_ $$aMay, Anne M$$b10
000132679 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b11$$eLast author$$udkfz
000132679 773__ $$0PERI:(DE-600)2004077-5$$a10.1007/s10549-017-4608-7$$gVol. 168, no. 2, p. 421 - 431$$n2$$p421 - 431$$tBreast cancer research and treatment$$v168$$x1573-7217$$y2018
000132679 909CO $$ooai:inrepo02.dkfz.de:132679$$pVDB
000132679 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000132679 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000132679 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000132679 9141_ $$y2018
000132679 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000132679 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBREAST CANCER RES TR : 2015
000132679 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000132679 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000132679 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000132679 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000132679 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000132679 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000132679 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000132679 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000132679 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000132679 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000132679 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000132679 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000132679 980__ $$ajournal
000132679 980__ $$aVDB
000132679 980__ $$aI:(DE-He78)G210-20160331
000132679 980__ $$aUNRESTRICTED